Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Sands, Michelle ^a   Howell, Katherine ^a   Costello, Christine M ^a   McLoughlin, Paul ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLACENTAL GROWTH FACTOR; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; FLT1 PROTEIN, RAT; PLACENTA PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; ASSAY; CONTROLLED STUDY; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS WALL; LUNG DISEASE; MALE; MICROENVIRONMENT; MONOLAYER CULTURE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STEREOMETRY; WESTERN BLOTTING; WOUND HEALING; ANIMAL; ANOXIA; CELL MOTION; DISEASE MODEL; GENETICS; LUNG; LUNG ALVEOLUS CELL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PULMONARY HYPERTENSION; SPRAGUE DAWLEY RAT; TIME; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; ANOXIA; BLOTTING, WESTERN; CELL MOVEMENT; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; PNEUMOCYTES; POLYMERASE CHAIN REACTION; PREGNANCY PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78951482247     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-17     Document Type: Article

References (63)

1. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med 1994, 150(4):1158-68.
2. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994, 150(3):833-52.
3. Mandegar M, et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004, 68(2):75-103. 10.1016/j.mvr.2004.06.001, 15313118.
4. Hyvelin JM, et al. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005, 97(2):185-91. 10.1161/01.RES.0000174287.17953.83, 15961717.
5. Howell K, Preston RJ, McLoughlin P. Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J Physiol 2003, 547(Pt 1):133-45. 10.1113/jphysiol.2002.030676, 2342608, 12562951.
6. Le Cras TD, et al. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 2002, 283(3):L555-62.
7. Oka M, et al. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007, 100(6):923-9. 10.1161/01.RES.0000261658.12024.18, 17332430.
8. Voelkel NF, et al. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med 2002, 30(5 Suppl):S251-6. 10.1097/00003246-200205001-00013, 12004244.
9. Partovian C, et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 2000, 23(6):762-71.
10. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005, 9(4):777-94. 10.1111/j.1582-4934.2005.tb00379.x, 16364190.
11. Wirzenius M, et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 2007, 204(6):1431-40. 10.1084/jem.20062642, 2118625, 17535974.
12. Ueda N, et al. Pseudocowpox virus encodes a homolog of vascular endothelial growth factor. Virology 2003, 305(2):298-309. 10.1006/viro.2002.1750, 12573575.
13. Staton CA, et al. Neuropilins in physiological and pathological angiogenesis. J Pathol 2007, 212(3):237-48. 10.1002/path.2182, 17503412.
14. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer 2008, 8(11):880-7. 10.1038/nrc2505, 2613352, 18923433.
15. Varet J, et al. VEGF in the lung: a role for novel isoforms. Am J Physiol Lung Cell Mol Physiol 2010, 298(6):L768-74. 10.1152/ajplung.00353.2009, 2886605, 20228180.
16. Park JE, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994, 269(41):25646-54.
17. DiSalvo J, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J Biol Chem 1995, 270(13):7717-23. 10.1074/jbc.270.13.7717, 7706320.
18. Eriksson A, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002, 1(1):99-108. 10.1016/S1535-6108(02)00028-4, 12086892.
19. Tsao PN, et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med 2004, 169(4):505-11. 10.1164/rccm.200306-774OC, 14644931.
20. Cheng SL, et al. Prevention of elastase-induced emphysema in placenta growth factor knock-out mice. Respir Res 2009, 10:115. 10.1186/1465-9921-10-115, 2789728, 19930612.
21. Cheng SL, et al. Increased expression of placenta growth factor in COPD. Thorax 2008, 63(6):500-6. 10.1136/thx.2007.087155, 2571977, 18202163.
22. Ooi H, et al. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol 2000, 278(2):H331-8.
23. Tsukimoto K, et al. Ultrastructural appearances of pulmonary capillaries at high transmural pressures. J Appl Physiol 1991, 71(2):573-82.
24. Bolender RP, Hyde DM, Dehoff RT. Lung morphometry: a new generation of tools and experiments for organ, tissue, cell, and molecular biology. Am J Physiol 1993, 265(6 Pt 1):L521-48.
25. Hsia CC, et al. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010, 181(4):394-418. 10.1164/rccm.200809-1522ST, 20130146.
26. Gundersen HJ, et al. The efficiency of systematic sampling in stereology--reconsidered. J Microsc 1999, 193(Pt 3):199-211. 10.1046/j.1365-2818.1999.00457.x, 10348656.
27. Howell K, Hopkins N, McLoughlin P. Combined confocal microscopy and stereology: a highly efficient and unbiased approach to quantitative structural measurement in tissues. Exp Physiol 2002, 87(6):747-56. 10.1113/eph8702477, 12530405.
28. Howell K, et al. L-Arginine promotes angiogenesis in the chronically hypoxic lung: a novel mechanism ameliorating pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009, 296(6):L1042-50. 10.1152/ajplung.90327.2008, 19346433.
29. Cadogan E, et al. Enhanced expression of inducible nitric oxide synthase without vasodilator effect in chronically infected lungs. Am J Physiol 1999, 277(3 Pt 1):L616-27.
30. Costello CM, et al. Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008, 295(2):L272-84. 10.1152/ajplung.00358.2007, 18469115.
31. Cunningham EL, Brody JS, Jain BP. Lung growth induced by hypoxia. J Appl Physiol 1974, 37(3):362-6.
32. Kay JM, Suyama KL, Keane PM. Failure to show decrease in small pulmonary blood vessels in rats with experimental pulmonary hypertension. Thorax 1982, 37(12):927-30. 10.1136/thx.37.12.927, 459460, 6820578.
33. Mehta S, et al. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995, 92(6):1539-45.
34. Mitani Y, Maruyama K, Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 1997, 96(2):689-97.
35. Nagaoka T, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005, 171(5):494-9. 10.1164/rccm.200405-637OC, 15563635.
36. Partovian C, et al. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 1998, 275(6 Pt 2):H1948-56.
37. Rabinovitch M, et al. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol 1979, 236(6):H818-27.
38. Pascaud MA, et al. Lung overexpression of angiostatin aggravates pulmonary hypertension in chronically hypoxic mice. Am J Respir Cell Mol Biol 2003, 29(4):449-57. 10.1165/rcmb.2002-0120OC, 12714372.
39. Yamaji-Kegan K, et al. Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. Am J Physiol Lung Cell Mol Physiol 2006, 291(6):L1159-68. 10.1152/ajplung.00168.2006, 16891392.
40. Yamaji-Kegan K, et al. IL-4 is proangiogenic in the lung under hypoxic conditions. J Immunol 2009, 182(9):5469-76. 10.4049/jimmunol.0713347, 19380795.
41. Berg JT, et al. Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor-B in lung parenchyma. Am J Respir Crit Care Med 1998, 158(6):1920-8.
42. Kugathasan L, et al. Role of angiopoietin-1 in experimental and human pulmonary arterial hypertension. Chest 2005, 128(6 Suppl):633S-642S. 10.1378/chest.128.6_suppl.633S, 16373885.
43. Pfeifer M, et al. Vascular remodeling and growth factor gene expression in the rat lung during hypoxia. Respir Physiol 1998, 111(2):201-12. 10.1016/S0034-5687(97)00102-3, 9574871.
44. Christou H, et al. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1998, 18(6):768-76.
45. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995, 95(4):1798-807. 10.1172/JCI117858, 295709, 7706486.
46. Yamamoto A, et al. Downregulation of angiopoietin-1 and Tie2 in chronic hypoxic pulmonary hypertension. Respiration 2008, 75(3):328-38. 10.1159/000112432, 18073453.
47. Engebretsen BJ, et al. Acute hypobaric hypoxia (5486 m) induces greater pulmonary HIF-1 activation in hilltop compared to madison rats. High Alt Med Biol 2007, 8(4):312-21. 10.1089/ham.2007.1031, 18081507.
48. Li H, et al. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005, 26(2-3):210-7. 10.1016/j.placenta.2004.05.004, 15708122.
49. Sivakumar V, et al. Vascular endothelial growth factor and nitric oxide production in response to hypoxia in the choroid plexus in neonatal brain. Brain Pathol 2008, 18(1):71-85. 10.1111/j.1750-3639.2007.00104.x, 17924979.
50. Xu F, Severinghaus JW. Rat brain VEGF expression in alveolar hypoxia: possible role in high-altitude cerebral edema. J Appl Physiol 1998, 85(1):53-7.
51. Fechner G, et al. Evaluation of hypoxia-mediated growth factors in a novel bladder cancer animal model. Anticancer Res 2007, 27(6B):4225-31.
52. Itakura E, et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008, 97(1):74-81. 10.1002/jso.20766, 18041747.
53. Shimoda K, et al. Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Int J Oncol 1999, 14(2):353-9.
54. Tsai AG, et al. Microvascular and tissue oxygen gradients in the rat mesentery. Proc Natl Acad Sci USA 1998, 95(12):6590-5. 10.1073/pnas.95.12.6590, 22570, 9618456.
55. Leong CL, et al. Evidence that renal arterial-venous oxygen shunting contributes to dynamic regulation of renal oxygenation. Am J Physiol Renal Physiol 2007, 292(6):F1726-33. 10.1152/ajprenal.00436.2006, 17327497.
56. Archer SL, et al. Preferential expression and function of voltage-gated, O2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res 2004, 95(3):308-18. 10.1161/01.RES.0000137173.42723.fb, 15217912.
57. Leonard MO, et al. Hypoxia selectively activates the CREB family of transcription factors in the in vivo lung. Am J Respir Crit Care Med 2008, 178(9):977-83. 10.1164/rccm.200712-1890OC, 2643223, 18689465.
58. Milkiewicz M, et al. Vascular endothelial growth factor mRNA and protein do not change in parallel during non-inflammatory skeletal muscle ischaemia in rat. J Physiol 2006, 577(Pt 2):671-8. 10.1113/jphysiol.2006.113357, 1890445, 16990404.
59. Cao Y, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996, 271(6):3154-62. 10.1074/jbc.271.6.3154, 8621715.
60. Carmeliet P, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7(5):575-83. 10.1038/87904, 11329059.
61. Kasahara Y, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000, 106(11):1311-9. 10.1172/JCI10259, 387249, 11104784.
62. Bellomo D, et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000, 86(2):E29-35.
63. Mould AW, et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum 2003, 48(9):2660-9. 10.1002/art.11232, 13130487.